One in five patients with early AMD will progress to severe vision loss as they age. Macula Risk^® is a tool to identify which patients need to be monitored aggressively to preserve their vision.

Treat your Wet AMD patients earlier!

Data analyzed from the pivotal MARINA trial for Lucentis^® (ranibizumab) have demonstrated that the outcomes of treatment are best observed when the drug is administered early; when the lesions are small and outside the fovea².

Identify which patients need close monitoring and Save their Sight.